ERBB2 and gastric cancer: For this rare subset of patients with HER2-positive and MSI-H unresectable advanced gastric cancer, the optimal treatment strategy—whether chemotherapy plus trastuzumab or chemotherapy plus immune checkpoint inhibitors—has not yet been established.